Royalty Pharma (RPRX) Capital Expenditures (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Capital Expenditures data on file, last reported at $452.4 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 42697.16% year-over-year to $452.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (down 11.22% YoY), and the FY2025 full-year result was $1.7 billion, down 32.25% from the prior year.
• Capital Expenditures eased to $452.4 million in Q1 2026, from $733.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.3 billion in Q3 2022 to a low of $85000.0 in Q1 2022.
• A 5-year average of $500.8 million and a median of $452.4 million in 2026 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slumped 99.98% in 2022 and surged 707788.24% in 2023, its largest moves.
• Tracing RPRX's Capital Expenditures over 5 years: stood at $250.2 million in 2022, then soared by 300.51% to $1.0 billion in 2023, then tumbled by 50.47% to $496.4 million in 2024, then soared by 47.8% to $733.7 million in 2025, then slumped by 38.34% to $452.4 million in 2026.
• Business Quant data shows RPRX's Capital Expenditures at $452.4 million in Q1 2026, $733.7 million in Q4 2025, and $961.9 million in Q3 2025.